cookies on this device, please see our
cookie management page. If you close this message or continue to use this site, you consent
Specialist pharmaceutical group BTG (BTG) saw its shares rise 9 per cent on the back of these robust looking half-year figures - indeed, add back acquisition adjustments and reorganisation costs, and underlying operating profits rose 45 per cent to £59.5m. Moreover, strong cash flow from its existing drugs should support new product development.